Capricor TherapeuticsCAPR
CAPR
About: Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
Employees: 102
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
311% more capital invested
Capital invested by funds: $31.1M [Q2] → $128M (+$96.6M) [Q3]
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
46% more call options, than puts
Call options by funds: $33.4M | Put options by funds: $22.9M
23% more funds holding
Funds holding: 61 [Q2] → 75 (+14) [Q3]
5.52% more ownership
Funds ownership: 20.38% [Q2] → 25.89% (+5.52%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
119%
upside
Avg. target
$46
232%
upside
High target
$77
462%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 117 / 398 met price target | 462%upside $77 | Buy Reiterated | 2 Jan 2025 |
Jones Trading Catherine Novack 30% 1-year accuracy 3 / 10 met price target | 192%upside $40 | Buy Initiated | 18 Nov 2024 |
Cantor Fitzgerald Kristen Kluska 33% 1-year accuracy 35 / 107 met price target | 119%upside $30 | Overweight Maintained | 14 Nov 2024 |
Piper Sandler Edward Tenthoff 18% 1-year accuracy 8 / 45 met price target | 155%upside $35 | Overweight Initiated | 21 Oct 2024 |
Financial journalist opinion
Based on 3 articles about CAPR published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade
The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
2 weeks ago
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Neutral
GlobeNewsWire
2 weeks ago
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. “The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD.
Positive
Market Watch
1 month ago
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
Positive
Seeking Alpha
1 month ago
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached
Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significant improvements in upper limb function and LVEF in Phase 2 trials, with ongoing open-label extension trials supporting long-term efficacy and safety. Despite promising prospects, Capricor's upside is limited due to prior commercialization deals, but the stock remains attractively valued with potential milestone payments and royalties.
Positive
Seeking Alpha
1 month ago
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented promising 3-year data from the HOPE-2 OLE study, showing significant improvements in cardiac and skeletal muscle functions. Capricor raised $86.3 million in a public offering, ensuring sufficient cash runway to fund operations into 2027, excluding potential milestone payments from Nippon Shinyaku.
Neutral
GlobeNewsWire
1 month ago
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences.
Neutral
Seeking Alpha
2 months ago
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Rick Miller - Cantor Fitzgerald Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2024 Financial Results and Corporate Update Call.
Negative
Zacks Investment Research
2 months ago
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Charts implemented using Lightweight Charts™